Eperisone Hydrochloride Tablets

1. Relieve skeletal muscle hypertonia (1) Inhibit experimental spasticity. It can dose-dependently inhibit rat interthalamic transection spasticity (γ-tonicity) and ischemic cerebral spasticity (α-tonicity). (2) Inhibit spinal reflexes. In a spinal cat experiment, it can inhibit monosynaptic and polysynaptic reflex potentials caused by stimulation of the posterior roots of the cat spinal cord to the same extent. (3) Reduce the sensitivity of muscle spindles through the γ-system. It can inhibit the activity of afferent nerves (1α fibers) generated in human muscle spindles 30 minutes after administration. This product inhibits the spontaneous firing of animal γ-motor neurons, but does not directly act on muscle spindles. Therefore, it can be considered that this product reduces the sensitivity of muscle spindles with the help of the γ-system. 2. Dilate blood vessels and improve blood flow (1) Vasodilation can dilate blood vessels through calcium ion antagonism (rat pecking) and muscle sympathetic nerve inhibition (human). (2) Increase blood flow. In humans, monkeys and dogs, it can increase blood flow in the skin, muscles, external carotid artery, internal carotid artery and vertebral artery. 3. It has analgesic and pain reflex inhibitory effects. The results of the drug perfusing the spinal cord of rats to inhibit the pain reflex of tail pinch pain (TailPinch) and removing the drug showed that the drug showed analgesic effects at the spinal cord level. 4. It makes voluntary movements free. It can be used in cases of spastic paralysis such as stroke patients to improve the torque curve and electromyography of Cybex. Under the condition of reducing the strength of spastic muscles, the extension and bending movements of the upper and lower limbs are brisk and smooth, and voluntary movements are free. Toxicology study: Data show that long-term toxicity: SD rats were orally administered this product for 26 weeks or 52 weeks continuously, with a dose of 25.50, 100, and 200 mg/kg/day. No abnormalities were found in the 25 mg/kg group. Even the group above 50mg/kg did not have serious effects; beagle dogs were orally administered 10 and 25.625mg/kg/day for 53 consecutive weeks. No abnormalities were found in the 10mg/kg group. Although the group above 25mg/kg had vomiting, salivation, increased liver weight and mild hepatocyte enlargement, they recovered once the drug was discontinued. Reproductive toxicity test: SD rats were orally administered 25-500mg/kg/day before pregnancy and in the early stage of organ formation, during the perinatal period, during the lactation period, and rabbits during the organ formation period. The results showed that the maternal animals were affected when administered above 200mg/kg. Newborns in the perinatal and lactation period were found to have mild developmental delays, but no teratogenicity. There was no effect on the development of motor function, learning, reproductive function and F2 fetuses of newborns.

EperisoneHCl, 4-ethyl-2-methyl-3-piperidinylpropiophenone hydrochloride, has a molecular formula of C17H25NO·HCl and a molecular weight of 295.85.

This product is a light orange-white sugar-coated tablet, which appears white after removing the sugar coating.

Central muscle relaxant. 1. Used to improve the muscle tension of the following diseases: cervical back shoulder arm syndrome, frozen shoulder, low back pain; 2. Used to improve spastic paralysis caused by the following diseases: cerebrovascular disorder, spastic spinal cord paralysis, cervical spondylosis, surgical sequelae (including brain and spinal cord tumors), traumatic sequelae (spinal cord injury, head trauma), amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorder, subacute spinal cord neurosis (SMON) and other brain and spinal cord diseases.

Orally after meals. Usually adults take 1 tablet 3 times a day. Or as directed by your doctor.

1. The medication should be discontinued when the following adverse reactions occur: shock, abnormal liver function, abnormal kidney function, abnormal blood test (including red blood cell count, hemoglobin value); 2. The following adverse reactions may occur: Skin: rash, itching, etc.; Mental and nervous system: insomnia, headache, drowsiness, body stiffness, numbness of limbs, decreased perception, tremor of limbs, etc.; Digestive system: nausea, vomiting, loss of appetite, stomach discomfort, dry mouth, constipation, diarrhea, abdominal pain, abdominal distension, etc., occasionally stomatitis; Urinary system: urinary retention, urinary incontinence, feeling of incomplete urination, etc.; Systemic symptoms: weakness in limbs, unstable standing, general fatigue, occasionally dizziness, decreased muscle tension, etc.; Others: facial heat, sweating, etc.

It is contraindicated for patients with severe liver and kidney dysfunction, accompanied by shock, and breastfeeding women.

Precautions for children: There is no experience of using the drug in children, so it is not recommended. Precautions for pregnancy and lactation: 1. Pregnant women should use it with caution. 2. It is forbidden for breastfeeding women. Precautions for the elderly: In general, the physiological functions of the elderly are reduced, so please pay attention to taking measures such as reducing the dosage.

There have been reports of ocular accommodation disorders when a similar drug, tolperisone hydrochloride, is used in combination with methoxycarbamol.

Store away from moisture after opening.

50mg

Tentative 36 months

Sinopharm Yibin Pharmaceutical Co., Ltd.

• Founded in:

  1999-08-18

• Address:

  No. 1, Binjiang East Road, Luolong Industrial Concentration Zone, Yibin

• Tax NO.:

  91511500709060705C

• Registered Funds:

  33.3739 million yuan

• Website:

  Log in to view

• Email:

  Log in to view